Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Selecta Closes $15 Million Series C Financing

Abstract:
Company To Advance New Class of Synthetic Vaccines into Clinical Development based on targeted Synthetic Vaccine Particle (tSVP) platform

Selecta Closes $15 Million Series C Financing

Watertown, MA | Posted on April 5th, 2010

Selecta Biosciences, Inc., a biopharmaceutical company developing synthetic nanoparticle vaccines, today announced that it has raised $15 million in a Series C financing round. OrbiMed Advisors LLC led the round, with participation from existing investors Polaris Venture Partners, Flagship Ventures, NanoDimension and Leukon Investments. The Series C financing brings the total capital raised by Selecta over the past 15 months to more than $30 million.

Proceeds from the Series C financing will be used to expand Selecta's development of a new class of synthetic vaccines for prophylactic and therapeutic indications based on the company's proprietary targeted Synthetic Vaccine Particle (tSVP™) platform. The company's lead product candidate will enter first-in-human clinical evaluation in 2011. The tSVP platform is based on biodegradable polymeric nanoparticles that fully-integrate all the vaccine components for targeting to immune cells for optimal cellular or humoral immune response.

"We are delighted by the strong investor interest in this Series C financing which reflects the value created since our last round and speaks volumes to the potential of Selecta's platform and product pipeline," said Robert L. Bratzler, Ph.D., Executive Chairman of Selecta.

"This new financing will advance our breakthrough tSVP platform and take our lead product candidate through the initial clinical proof of concept evaluations," said Lloyd Johnston, Ph.D., Vice President of Pharmaceutical Research and Development of Selecta.

"Selecta's tSVP platform enables the development of targeted and fully integrated prophylactic and therapeutic vaccines and represents a truly revolutionary platform with the potential to leapfrog existing vaccine technologies," said Carl L. Gordon, Ph.D., founding General Partner of OrbiMed. "We believe Selecta's synthetic nanoparticle approach will have the potential to deliver safe and more effective vaccines for a broad range of diseases."

In connection with this financing, Dr. Gordon of OrbiMed will join the Board of Directors of Selecta, which is comprised of Robert Bratzler, Ph.D., Executive Chairman, Selecta Biosciences; Douglas Cole, M.D., General Partner, Flagship Ventures; Omid Farokhzad, M.D., Selecta Founder and Associate Professor, Harvard Medical School; Peter Hutt, Senior Counsel, Covington & Burling LLP; Robert Langer, Sc.D., Selecta Founder and Institute Professor, Massachusetts Institute of Technology; Amir Nashat, Ph.D., General Partner, Polaris Venture Partners; Aymeric Sallin, Managing Director and Founder, NanoDimension; and George Siber, M.D., Former Executive Vice President and Chief Scientific Officer, Wyeth Vaccines.

####

About Selecta Biosciences
Selecta Biosciences, Inc. is a biopharmaceutical company developing first-in-class synthetic nanoparticle vaccines using its proprietary targeted Synthetic Vaccine Particle (tSVP™) technology. The tSVP platform enables full-integration of the key vaccine components, antigens and adjuvants, for highly-effective targeting to immune cells to produce an optimal immune response. The tSVP vaccines mimics the structure of natural pathogens with regards to size, shape and the sequence of immunological information that it delivers to immune cells, thus harnessing the body’s defense system to produce a robust immune response. The unique attributes of full-integration, targeting and natural structure conferred by the tSVP platform create synthetic nanoparticle vaccines that are engineered for unprecedented safety and efficacy. This novel approach enables expanded opportunities for tSVP vaccines, and the company is pursuing opportunities across a range of clinical applications, including infectious, metabolic, CNS and inflammatory diseases.

Selecta was founded in 2008 by three academic pioneers in the fields of nanotechnology and immunology: Professor Robert Langer (MIT), and Professors Omid Farokhzad and Ulrich von Andrian (Harvard Medical School). Selecta is backed by leading venture investors including, Polaris Venture Partners, Flagship Ventures, NanoDimension, OrbiMed Advisors and Leukon Investments. For more information please visit the company website at www.selectabio.com.

For more information, please click here

Contacts:
The Yates Network
Adriana Jenkins
617-744-1713

Copyright © Selecta Biosciences

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

ANU invention to inspire new night-vision specs December 7th, 2016

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016

Journal Nanotechnology Progress International (JONPI), newest edition out December 7th, 2016

In IEDM 2016 Keynote, Leti CEO Says ‘Hyperconnectivity’, Human-focused Research and the IOT Promise Profound, Positive Changes December 7th, 2016

Investments/IPO's/Splits

Harris & Harris Group Issues Letter to Shareholders and Information for Shareholder Call on Tuesday, November 15, 2016 November 14th, 2016

Harris & Harris Group Issues Business Update and Reports Financial Statements as of September 30, 2016 November 9th, 2016

Forge Nano raises $20 million in Series A Funding: Nano coating technology innovator Forge Nano will use funding to expand manufacturing capacity and grow Lithium-Ion battery opportunities November 3rd, 2016

Harris & Harris Group Notes Announcements by Its Portfolio Companies During the Third Quarter of 2016 September 30th, 2016

Nanomedicine

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016

Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016

Journal Nanotechnology Progress International (JONPI) Volume 6, issue 2 coming out soon! December 5th, 2016

UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016

Announcements

ANU invention to inspire new night-vision specs December 7th, 2016

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016

Journal Nanotechnology Progress International (JONPI), newest edition out December 7th, 2016

In IEDM 2016 Keynote, Leti CEO Says ‘Hyperconnectivity’, Human-focused Research and the IOT Promise Profound, Positive Changes December 7th, 2016

Appointments/Promotions/New hires/Resignations/Deaths

Dr Barbara Armbruster promoted to Worldwide Sales and Marketing Director for XEI Scientific September 27th, 2016

Dr Barbara Armbruster joins XEI Scientific as Marketing Director June 1st, 2016

Park Systems Global Expansion in AFM Market Includes Appointment of New Executives April 23rd, 2016

GLOBALFOUNDRIES Adds Alain Mutricy as Head of Product Management Group March 3rd, 2016

Nanobiotechnology

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016

Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016

Deep insights from surface reactions: Researchers use Stampede supercomputer to study new chemical sensing methods, desalination and bacterial energy production December 2nd, 2016

Nanobiotix Provides Update on Global Development of Lead Product NBTXR3: Seven clinical trials across the world: More than 2/3 of STS patients recruited in the “act.in.sarc” Phase II/III trial: Phase I/II prostate cancer trial now recruiting in the U.S. November 28th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project